RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Recruiting · NCT06216938 · Registry updated 2026-04-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Early phase 1 | 2026-04-13 | NCT06216938 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Replimune, Inc. | 14 |
| Yana Najjar | 6 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UPMC Hillman Cancer Center | Pittsburgh | United States | 330 |